--- title: "Perrigo’s Q2 Return To Profit Amid Lower Sales Might Change The Case For Investing In PRGO" type: "News" locale: "en" url: "https://longbridge.com/en/news/296008507.md" description: "Perrigo reported a Q2 2026 net income of $74.5 million, marking a return to profitability compared to the prior year's loss, despite overall sales declining to $1,022.8 million. The company reaffirmed its full-year guidance for an all-in net sales decline between 1.5% and 5.5%. While quarterly earnings improved, Perrigo remains loss-making for the first half of 2026 with a $324.1 million H1 loss. Analysts suggest that margin improvements during falling sales are key, though risks from weak OTC demand and infant formula competition persist." datetime: "2026-08-15T23:43:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296008507.md) - [en](https://longbridge.com/en/news/296008507.md) - [zh-HK](https://longbridge.com/zh-HK/news/296008507.md) generator: "portal-rs" --- # Perrigo’s Q2 Return To Profit Amid Lower Sales Might Change The Case For Investing In PRGO - Perrigo Company plc recently reported its second-quarter 2026 results, with sales of US$1,022.8 million and net income of US$74.5 million, and reaffirmed full-year 2026 guidance calling for an All In net sales decline of between 5.5% and 1.5%. - The quarter marked a shift from a net loss a year earlier to positive earnings per share, even as both quarterly and year-to-date sales fell compared with 2025 and the company remained loss-making over the first half. - We’ll now examine how Perrigo’s move from quarterly net loss to net income, while reaffirming guidance, may influence its investment narrative. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource. ## Perrigo Investment Narrative Recap To own Perrigo, you have to believe in the long term appeal of affordable OTC and self care products, even as near term growth remains pressured. The latest quarter’s return to positive earnings, paired with reaffirmed guidance for a full year sales decline of 5.5% to 1.5%, suggests the main short term catalyst is whether margin improvements can stick while sales are falling. The biggest risk remains weak category demand and competitive pressure in OTC and infant formula, which this update does not materially change. Among recent announcements, the reaffirmed 2026 outlook is most relevant here. Despite Q2 net income of US$74.5 million, Perrigo still posted a US$324.1 million loss for the first half as sales declined versus 2025, and management kept its expectation for lower All In net sales this year. That combination of improving quarterly profitability but a still loss making first half keeps attention firmly on execution in the core OTC and nutrition businesses as the key near term swing factor. Yet investors should also weigh the risk that ongoing weak category consumption and intense promotion in infant formula could persist longer than expected and... Read the full narrative on Perrigo (it's free!) Perrigo’s narrative projects $4.2 billion revenue and $73.4 million earnings by 2029. This implies fairly flat yearly revenue growth and a roughly $1.9 billion earnings increase from -$1.8 billion today. Uncover how Perrigo's forecasts yield a $16.50 fair value, a 27% upside to its current price. ## Exploring Other Perspectives PRGO 1-Year Stock Price Chart Some of the lowest tier analysts were already assuming roughly flat revenue near US$4.1 billion and only US$92.9 million of earnings by 2029, so if you worry about prolonged category softness and retailer pressure on margins, this new guidance reaffirmation might push you to revisit whether that more pessimistic path still feels too harsh or perhaps closer to your own view. Explore 4 other fair value estimates on Perrigo - why the stock might be worth just $16.50! ## The Verdict Is Yours Don't just follow the ticker - dig into the data and build a conviction that's truly your own. - A great starting point for your Perrigo research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. - Our free Perrigo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Perrigo's overall financial health at a glance. ## Ready To Venture Into Other Investment Styles? Our daily scans reveal stocks with breakout potential. Don't miss this chance: - Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution. - Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. - The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [PRGO.US](https://longbridge.com/en/quote/PRGO.US.md) ## Related News & Research - [Perrigo Company Reaffirms Full-Year 2026 Outlook](https://longbridge.com/en/news/294973320.md) - [PRGO: Structural improvements and a diversified portfolio drive growth in a resilient healthcare market](https://longbridge.com/en/news/295680501.md) - [Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference | PRGO Stock News](https://longbridge.com/en/news/287634878.md) - [Abbott settles appeal over $495 million infant formula verdict](https://longbridge.com/en/news/296386129.md) - [SS&C GlobeOp Forward Redemption Indicator | SSNC Stock News](https://longbridge.com/en/news/296609710.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**